Reviewer’s report

Title: Early onset recall pneumonitis during targeted therapy with sunitinib

Version: 1 Date: 14 October 2012

Reviewer: Christoph Seidel

Reviewer’s report:

1) The text passage (sunitnib) ... it is the best agent available in the United States for patients with metastatic RCC can be excluded.

The statement sunitinib is the best agent should be avoided in this context.

Particularly due to the fact that direct head to head studies with activity analyses between to substances (such as sunitinib versus pazopanib) are not published yet. On the other hand more active substances such as tivozanib and axitinib will enter the market.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests' below.